Bolt Biotherapeutics Statistics Share Statistics Bolt Biotherapeutics has 1.92M
shares outstanding. The number of shares has increased by 0.2%
in one year.
Shares Outstanding 1.92M Shares Change (YoY) 0.2% Shares Change (QoQ) 0% Owned by Institutions (%) 47.8% Shares Floating 1.26M Failed to Deliver (FTD) Shares 1,270 FTD / Avg. Volume 4.54%
Short Selling Information The latest short interest is 86.94K, so 4.54% of the outstanding
shares have been sold short.
Short Interest 86.94K Short % of Shares Out 4.54% Short % of Float 4.54% Short Ratio (days to cover) 4.02
Valuation Ratios The PE ratio is -6.47 and the forward
PE ratio is -0.26.
Bolt Biotherapeutics's PEG ratio is
0.66.
PE Ratio -6.47 Forward PE -0.26 PS Ratio 53.13 Forward PS 2.7 PB Ratio 7.14 P/FCF Ratio -6.66 PEG Ratio 0.66
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Bolt Biotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.2,
with a Debt / Equity ratio of 0.44.
Current Ratio 3.2 Quick Ratio 3.2 Debt / Equity 0.44 Debt / EBITDA -0.38 Debt / FCF -0.41 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $147.88K Profits Per Employee $-1.21M Employee Count 52 Asset Turnover 0.08 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -59.84% in the
last 52 weeks. The beta is 0.9, so Bolt Biotherapeutics's
price volatility has been higher than the market average.
Beta 0.9 52-Week Price Change -59.84% 50-Day Moving Average 5.96 200-Day Moving Average 8.73 Relative Strength Index (RSI) 41.97 Average Volume (20 Days) 28,003
Income Statement In the last 12 months, Bolt Biotherapeutics had revenue of 7.69M
and earned -63.12M
in profits. Earnings per share was -1.65.
Revenue 7.69M Gross Profit 5.51M Operating Income -73.05M Net Income -63.12M EBITDA -66.45M EBIT -68.24M Earnings Per Share (EPS) -1.65
Full Income Statement Balance Sheet The company has 7.21M in cash and 25.21M in
debt, giving a net cash position of -18M.
Cash & Cash Equivalents 7.21M Total Debt 25.21M Net Cash -18M Retained Earnings -427.4M Total Assets 85.86M Working Capital 28.95M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -61.29M
and capital expenditures -41K, giving a free cash flow of -61.33M.
Operating Cash Flow -61.29M Capital Expenditures -41K Free Cash Flow -61.33M FCF Per Share -1.61
Full Cash Flow Statement Margins Gross margin is 71.64%, with operating and profit margins of -949.91% and -820.78%.
Gross Margin 71.64% Operating Margin -949.91% Pretax Margin -820.78% Profit Margin -820.78% EBITDA Margin -864.17% EBIT Margin -949.91% FCF Margin -797.53%
Dividends & Yields BOLT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for BOLT is $50,
which is 788.1% higher than the current price. The consensus rating is "Hold".
Price Target $50 Price Target Difference 788.1% Analyst Consensus Hold Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 9, 2025. It was a
backward
split with a ratio of 1:20.
Last Split Date Jun 9, 2025 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -8.97 Piotroski F-Score 2
